Insmed Incorporated (INSM)

24,92 -0,89 (-3,45%) Alla chiusura: 04:00PM EDT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 912

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. William H. Lewis J.D., M.B.A.	President, CEO & Chairman	1,59M	1,11M	1969
Ms. Sara M. Bonstein M.B.A.	Chief Financial Officer	810,4k	N/D	1981
Mr. Roger Adsett M.B.A.	Chief Operating Officer	1,01M	N/D	1969
Mr. John Drayton Wise M.B.A.	Chief Commercial Officer	888,85k	N/D	1975
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer	872,29k	179,49k	1964
Mr. Brian K. Kaspar Ph.D.	Chief Scientific Officer	N/D	N/D	1974
Eleanor Barisser	Associate Director of Investor Relations	N/D	N/D	N/D
Mr. Michael Alexander Smith J.D.	Chief Legal Officer & Corporate Secretary	N/D	N/D	1978
Mandy Fahey	Executive Director of Corporate Communications	N/D	N/D	N/D
Ms. S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer	660,81k	1,18M	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Insmed Incorporated al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.